Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.

Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO.

Cochrane Database Syst Rev. 2018 Aug 24;8:CD012464. doi: 10.1002/14651858.CD012464.pub2. Review.

2.

Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.

Fakkert IE, van der Veer E, Abma EM, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, Slart RH, Westrik IG, de Bock GH, Mourits MJ.

PLoS One. 2017 Jan 6;12(1):e0169673. doi: 10.1371/journal.pone.0169673. eCollection 2017.

3.

Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.

Garcia C, Lyon L, Conell C, Littell RD, Powell CB.

Gynecol Oncol. 2015 Sep;138(3):723-6. doi: 10.1016/j.ygyno.2015.06.020. Epub 2015 Jun 16.

PMID:
26086567
4.

Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.

Fakkert IE, Abma EM, Westrik IG, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, Slart RH, van der Veer E, de Bock GH, Mourits MJ.

Eur J Cancer. 2015 Feb;51(3):400-8. doi: 10.1016/j.ejca.2014.11.022. Epub 2014 Dec 18.

5.

Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.

Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Gui G; Breast Unit of the Royal Marsden NHS Foundation Trust, Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R.

Clin Cancer Res. 2006 Dec 1;12(23):7025-32.

6.

Reducing the risk of breast cancer with tamoxifen in women at increased risk.

Vogel VG.

J Clin Oncol. 2001 Sep 15;19(18 Suppl):87S-92S. Review.

PMID:
11560980

Supplemental Content

Loading ...
Support Center